Indeed, when we treated the melanoma cell line MelJuso (HRASG13D/NRASQ61L) with 1 μM selumetinib this strongly and immediately inhibited ERK1/2 signalling and increased the expression of DYRK1B after a delay of 8 h. The gene discussed is MAPK3; the disease is melanoma.